A Japanese Enzyme Clinically Studied for Plaque Reduction in Your Arteries
A 12-month clinical study of 1,062 adults reported a 36.6% average reduction in carotid artery plaque. Below is my breakdown of the research, the doses that worked, and what I look for when recommending it to patients.
What the Clinical Studies Actually Measured
The Takayama study followed 29,000 adults in central Japan for sixteen years. Not a supplement trial. A dietary study. The residents who ate the most natto died of cardiovascular disease 43% less often. Unfermented soy showed no effect. The enzyme was doing the work.
In 2017, Ren and colleagues documented a 36.6% reduction in carotid artery plaque over twenty-six weeks of nattokinase supplementation.
Then came Chen 2022. The largest nattokinase trial to date. 1,062 adults. Twelve months. Published in Frontiers in Cardiovascular Medicine.
The group taking roughly 10,800 FU per day showed measurable plaque reduction on ultrasound. Blood pressure improved. Triglycerides improved. LDL cholesterol improved.
The group taking roughly 3,600 FU per day saw none of those changes.
Why a 36.6% Reduction Changes the Whole Picture
In cardiovascular research, every 1% reduction in arterial plaque is associated with roughly 25% lower risk of a cardiovascular event. The higher-dose group averaged 36.6%. That number does not just change a scan. It changes the conditions that drive multiple risk factors at once.
It Does Something Heart Medication Was Never Built to Do
Most of my patients are already doing something for their heart. A statin. A blood pressure pill. Aspirin. Diet changes. Walking. These are good steps. Each one targets one piece of the picture.
None of them break down fibrin.
Fibrin is the tough protein mesh that builds up inside artery walls over a lifetime. Aspirin stops new clots from forming. It does not clear what is already there. A statin lowers cholesterol production. It does not address the structural buildup that has been layering on for decades.
Nattokinase is one of the very few natural compounds clinically studied to support the body’s own ability to break down that existing buildup. It fills a gap none of those other steps were designed to fill. That is why I stopped thinking of it as a competitor to what my patients are already doing and started thinking of it as the missing piece.
Most Nattokinase Never Reaches Your Bloodstream
Nattokinase is a protein. Stomach acid breaks down proteins. A standard capsule dissolves in the stomach within minutes. The enzyme gets destroyed before it reaches the small intestine, where absorption actually happens.
Enteric coating is a pH-sensitive barrier that stays intact in stomach acid and dissolves only in the intestines. The enzyme arrives whole. Most nattokinase products do not use it. If the label does not say enteric-coated, assume it is a standard capsule.
The Formula I Could Not Find on a Shelf — So I Started Recommending This One
For years, I wrote down an ingredient list and told patients to assemble it themselves. The enzyme, the co-factors, the right capsule type. Most of them never did. Nobody wants to take seven capsules from seven bottles every morning.
The product I now point patients toward is called Hale Heart.
10,000 FU of nattokinase per serving with enteric coating. Aligned with the dose range that produced the headline results in the Chen 2022 trial. The lower-dose arm saw nothing. Hale Heart is built on the dose that worked.
Paired with CoQ10 for heart muscle energy. Bromelain, turmeric, and ginger for a healthy inflammatory response. Olive leaf for vascular support. White willow bark for healthy circulation.
Every ingredient on the label with its exact dose. Third-party tested. No proprietary blends. Enteric-coated capsules designed to deliver the enzyme past stomach acid intact.
What Patients Are Telling Me
- Chen H, et al. (2022). Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, 9, 964977.
- Ren NN, et al. (2017). A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Zhonghua Yi Xue Za Zhi, 97(26), 2038-2042.
- Nagata C, et al. (2017). Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: The Takayama study. American Journal of Clinical Nutrition, 105(2), 426-431.
- Sumi H, et al. (1990). Enhancement of the Fibrinolytic Activity in Plasma by Oral Administration of Nattokinase. Acta Haematologica, 84(3), 139-143.
